2014 Archived Content

Cambridge Healthtech Institute’s Second Annual

Companion Diagnostics

Implementing the New Standard

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA  

 

Day 1 | Day 2 | Day 3Download Brochure 

Tuesday, February 11 

7:00 am Registration and Morning Coffee 


8:00 Plenary Keynote Session (Click Here For More Details)  


9:15 Refreshment Break in the Exhibit Hall with Poster Viewing 


10:15 A Few Crisp Comments by a Former FDA Leader on the Current Need for More FDA Reform Similar to What We Did Before 

John A. Norris, J.D., MBA, Chairman, Norris Capital, Inc. and FDDH, Inc.; Senior US Advisor to Kanagawa, Japan, Governor Kuroiwa and GCC; Former 2nd-in-Command of the US FDA 

This presentation discusses the efforts of the Global Collaborative Center (GCC) in helping to reform the U.S. FDA’S review methods and standards relating to diagnostics and other medical solutions like drugs and devices.

10:25 REGULATORY PANEL DISCUSSION: Late-Breaking News from the FDA that Impacts
in vitro Diagnostic Tests 

Moderator:Thomas F. Soriano, President & CEO, DOCRO, Inc.

This session will feature guest speakers from the FDA and industry who will discuss late-breaking news related to companion diagnostics (CDx), next-generation sequencing, (NGS), laboratory-developed tests (LDTs), including guidance documents. Coordination of the pharmaceutical and diagnostic components for approval will be discussed - questions having to do with the process for approval of drugs that require a CDx, what to do with the various data, and how to anticipate requirements during the clinical stages of development will be discussed.

Guest Speaker via Webex: Alberto Gutierrez, Ph.D., Director,  Office of in Vitro Diagnostics (OIR), FDA

Richard Naples, Senior Vice President, Worldwide Corporate Regulatory Affairs, Becton-Dickinson

Michael Page, Ph.D., Senior Director, Oncology, Global Regulatory Affairs, Eisai, Inc.

Daniel J. O'Shannessy, Ph.D., Senior Director, Translational Medicine & Diagnostics, Morphotek



 

12:00 pm Optimizing Evidence Development and Communication to Support Market Access for Molecular Diagnostics 

Joseph V. Ferrara, President, Boston Healthcare

Learn how the landscape for molecular diagnostics is evolving in terms of market access pathways and clinical evidence requirements. Attendees will gain an understanding of the challenges of aligning evidence development programs to support clinical positioning, market adoption, and payer reimbursement and funding.  Best practices for collaborations between clinical development and commercialization strategy teams will be reviewed and highlighted, as well as key elements of successful transitions from clinical development to commercialization and payer engagement.

12:30 pm Session Break 

12:40 Luncheon Presentation I: Personalized Patient Therapy with Pharmacogenetics 

Stuart A. Scott, Ph.D., Assistant Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

1:10 Luncheon Presentation II: Washington Legal Update – Strategies for Navigating Key Reimbursement and FDA Issues for Diagnostics

Torrey Cope, J.D., Partner, FDA Regulatory, Sidley Austin LLP

Barbara Cammarata, J.D., M.P.H., Counsel, Health Care Regulatory/Reimbursement, Sidley Austin LLP

Dora L Hughes, M.D., M.P.H., Senior Policy Advisor, Government Strategies, Sidley Austin LLP

This session will feature an FDA lawyer, a health care reimbursement/CLIA/fraud and abuse lawyer, and a government strategies expert who will discuss some of the key legal and policy issues facing diagnostics companies in the current regulatory environment. The panel will explain practical strategies companies may employ to address legal challenges related to commercializing and marketing their products under FDA and health care requirements, as well as strategies to obtain appropriate reimbursement and to comply with government and private payor reimbursement requirements. It will also cover the industry’s role in developing law and policy to address the unique challenges in the emerging areas of in vitro diagnostics, companion diagnostics, molecular pathology and next generation sequencing.

1:40 Refreshment Break in the Exhibit Hall with Poster Viewing 

2:15 STRATEGIC PANEL DISCUSSION: Recent Companion Diagnostic Drug Approvals 

Moderator: Hakan Sakul, Ph.D., Executive Director and Head, Diagnostics, Worldwide R&D, Development Operations, Pfizer, Inc.

Overview on diagnostic commercialization, reading market forces and what it takes to make a success.

Ron Mazumder, Ph.D., MBA, Global Head, Research & Product Development, Janssen/J&J

Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex

Eric Lai, Ph.D., Senior Vice President & Head, Pharmacogenomics, Takeda Pharmaceuticals

Gregory Zdechlik, COO, Eli Lilly & Co.

4:20 Late Breaking Presentation

4:35 Valentine’s Day Celebration in the Exhibit Hall with Poster Viewing


5:20 Breakout Discussions in the Exhibit Hall

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.

Real World Coverage and Reimbursement: Implications for Molecular Testing

William McGivney, Ph.D., Principal, McGivney Global Advisors LLC

  • Coverage hurdles to the introduction, use, and payment for molecular tests
  • Inside the coverage processes and considerations of public and private payers
  • Impact of guidelines, pathways, electronic decision-assist tools, etc.
  • The setting of reimbursement levels in an environment of change in payment methodologies

Taking the Cardiac Biomarker ST2 from Discovery to Clinical Adoption

James V. Snider, Ph.D., President, Critical Diagnostics

  • Defining clinical utility for a novel test
  • Developing and IVD test and technology options
  • Regulatory, coding and reimbursement

How Do Diagnostic Providers Demonstrate Clinical Utility and Cost-Effectiveness? 

Harry Glorikian, Managing Director, Strategy, Precision for Medicine

  • How did you identify the clinical need you are aiming to address?
  • Who is your customer and how will you demonstrate clinical utility to justify this additional step?
  • How will you demonstrate cost-effectiveness to justify this additional cost?
  • How will you drive adoption and reach your customer base?

Big Data's Big Role in Understanding Complex Diseases

Andreas Kogelnik, M.D., Ph.D., Founder and Director, Open Medicine Institute

  • High performance platform for integrating molecular/genomic and clinical data
  • Applying science and medicine to crowd-sourced data
  • Enabling longitudinal outcomes studies with genomics and informatics
 

6:30 Close of Day 



Day 1 | Day 2 | Day 3Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 MMTC Final Agenda 

Premier Sponsors:

Abbott Molecular 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large 






Local Partners:

BayBio 


biocube 


Cabs 

City of SSF